CAR T-cell therapy is a type of specialized immunotherapy that uses the patient's own modified T-cells to fight cancer. It is approved to treat certain blood cancers like lymphoma, leukemia, and multiple myeloma.

Advanced age has traditionally been seen as prohibitive for treatments like stem cell transplants and CAR T therapy. This presentation reviews evidence that overall fitness is a crucial factor in reducing non-relapse mortality and that otherwise healthy elderly patients can have successful outcomes after transplant and CAR T-cell therapy.

La terapia de células CAR T es un tratamiento nuevo para pacientes que tienen ciertos tipos de linfoma no Hodgkin. Conozca lo que implica someterse a una terapia de células CAR T, quién es un buen candidato y los posibles resultados.

CAR T therapy (chimeric antigen receptor therapy) is a new treatment strategy that has been shown to improve patient outcomes. In this lecture, Dr. William reviews the steps involved, including T-cell collection, lymphodepleting chemotherapy, reinfusion of T-cells, and follow-up care. Potential side effects and their treatments are discussed as wel

La terapia de Células CAR-T es una nueva terapia para pacientes con mieloma múltiple. Esta presentación explica qué es la terapia de Células CAR-T, cuál es su eficacia para los pacientes con mieloma y los posibles efectos secundarios.

CAR T-cell therapy is an exciting second-line option for patients living with relapsed multiple myeloma. In this presentation, Dr. Ahmed reviews each step in the CAR T process and discusses a number of studies that support its use. Potential side effects are reviewed, and exciting future trends are discussed.

La terapia de células CAR T es una nueva opción de tratamiento para pacientes con leucemia linfoblástica aguda, algunos linfomas y mieloma múltiple que no han respondido a terapias anteriores. Esta presentación describe cómo funciona la terapia de células CAR T, sus riesgos y efectos secundarios, y cómo estos pueden manejarse de manera efectiva.

The age of patients undergoing a stem cell transplant or CAR T-cell therapy is increasing, but older patients are often not as fit as younger adults. Transplant and CAR T-cell therapies can be modified to increase the likelihood of success for old adults.

CAR T-cell therapy is a new treatment option for patients with acute lymphoblastic leukemia, some lymphomas, and multiple myeloma that have not responded to prior therapies. This presentation describes how CAR T-cell therapy works, its risks and side effects, and how these may be effectively managed.